valsartan

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Diastolic Dysfunction, Symptomatic Heart Failure

Conditions

Diastolic Dysfunction, Symptomatic Heart Failure

Trial Timeline

Dec 1, 2002 → Feb 1, 2008

NCT ID

NCT00171106

About valsartan

valsartan is a approved stage product being developed by Novartis for Diastolic Dysfunction, Symptomatic Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00171106. Target conditions include Diastolic Dysfunction, Symptomatic Heart Failure.

What happened to similar drugs?

2 of 3 similar drugs in Diastolic Dysfunction, Symptomatic Heart Failure were approved

Approved (2) Terminated (0) Active (1)

✅regadenosonAstellas PharmaApproved

✅ValsartanNovartisApproved

🔄Sildenafil + PlaceboPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01541189	Approved	Completed	Feb 1, 2012	Jan 1, 2013	Hypertension
NCT00627991	Pre-clinical	Withdrawn	Aug 1, 2007	—	Cerebrovascular Accident
NCT00550095	Approved	Completed	Jun 1, 2007	Nov 1, 2009	Microalbuminuria
NCT00457626	Phase 3	Completed	Apr 9, 2007	May 25, 2009	Hypertension
NCT01425411	Approved	Completed	Nov 1, 2006	Nov 1, 2008	Hypertension
NCT00589732	Approved	Completed	Sep 1, 2006	Dec 1, 2009	Coronary Artery Disease
NCT00415883	Phase 1	Completed	Jul 1, 2006	—	Healthy
NCT00394745	Phase 3	Completed	Nov 1, 2005	Jun 1, 2007	Hypertension
NCT00343499	Approved	Terminated	Nov 1, 2004	Jul 1, 2007	Atrial Fibrillation
NCT00170924	Approved	Completed	Aug 1, 2004	Jun 1, 2006	Diastolic Dysfunction
NCT00171353	Approved	Completed	Jul 1, 2004	Sep 1, 2005	Hypertension
NCT00333489	Approved	Completed	Mar 1, 2004	Apr 1, 2005	Hypertension
NCT00171119	Approved	Terminated	Jan 1, 2004	—	Hypertension
NCT00171028	Phase 3	Completed	Dec 1, 2003	Nov 1, 2006	Hypertension
NCT00241137	Phase 3	Completed	Sep 1, 2003	Jan 1, 2005	Hypertension
NCT00241098	Approved	Completed	May 1, 2003	Jun 1, 2005	Hypertension
NCT00171041	Phase 3	Completed	Dec 1, 2002	Mar 1, 2006	Hypertension
NCT00171106	Approved	Completed	Dec 1, 2002	Feb 1, 2008	Diastolic Dysfunction, Symptomatic Heart Failure
NCT00241150	Approved	Completed	Nov 1, 2002	Jan 1, 2005	Hypertension
NCT00241085	Approved	Completed	Nov 1, 2002	Aug 1, 2005	PROTEINURIA

Competing Products

6 competing products in Diastolic Dysfunction, Symptomatic Heart Failure

See all competitors

Product	Company	Stage	Hype Score
regadenoson	Astellas Pharma	Approved	43
Dapagliflozin + Placebo	AstraZeneca	Phase 2	31
Valsartan	Novartis	Approved	43
Ranolazine	Gilead Sciences	Phase 2	35
Sitexsentin sodium + Placebo	Pfizer	Phase 2	35
Sildenafil + Placebo	Pfizer	Phase 3	40